Loading...
News Category – All News2021-12-04T08:58:58-08:00

Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia

June 6th, 2024|

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

May 7th, 2024|

Soleno Therapeutics Received Breakthrough Therapy Designation from U.S.FDA For DCCR (Diazoxide Choline) Extended-Release Tables in Prader-Willi (PWS)

April 29th, 2024|

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion in Cash, Leveraging Povetacicept for IgA Nephropathy and Autoimmune Diseases

April 10th, 2024|

Evaheart Launches EVA-Pulsar™, Second Generation Destination Therapy Left Ventricular Assist Device (LVAD) Treating Heart Failure Patients

March 4th, 2024|

RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication

July 4th, 2023|

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 

November 30th, 2021|

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

November 23rd, 2021|

Vivo Capital’s Portfolio Co-Founder, Professor Frances Arnold, is Awarded as the First American Woman to Win the Nobel Prize in Chemistry.

January 15th, 2021|

Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine

December 3rd, 2018|

Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

November 8th, 2018|
Go to Top